<DOC>
	<DOCNO>NCT02915835</DOCNO>
	<brief_summary>The primary objective study provide preliminary data efficacy ( digital ulcer net burden ) safety riociguat administer 3 time daily ( TID ) comparison placebo patient scleroderma-associated digital ulcer</brief_summary>
	<brief_title>Riociguat Scleroderma Associated Digital Ulcers</brief_title>
	<detailed_description>This clinical trial US , multicenter , double-blind , randomize placebo-controlled , parallel- group study total 20 participant plan randomize ( approximately 10 participant riociguat group 10 placebo group ) . In addition , standardize wound care protocol follow investigator digital photography take cardinal ulcer . The study allow standard care medication management DU background therapy . These may include calcium channel blocker , low dose aspirin , angiotensin enzyme inhibitor , etc . determine participant 's local physician . The study design consist three phase : - Screening phase : 2 week - Double-blind Treatment phase : 16 week double-blind treatment , consist : - Dose titration period 8 week , - Stable dosing period 8 week - Open-label Extension phase participant active DU end double- blind treatment phase development active DU within month complete double-blind phase , consist : - Dose titration phase 8 week - Stable dosing period 8 week</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Skin Ulcer</mesh_term>
	<criteria>1 . Signed write informed consent 2 . Men woman age 18 year old 3 . Diagnosis Systemic sclerosis , define 2013 American College Rheumatology/ European Union League Against Rheumatism classification SSc 4 . Patients least one visible , active ischemic DU baseline locate distal proximal interphalangeal joint , develop worsen within 8 week prior screen . NOTE : Presence eschar consider active ulcer 5 . Females reproductive potential ( FRP ) must negative , pretreatment urine pregnancy test . 6 . FRP must obtain monthly urine pregnancy test treatment one month treatment discontinuation . Postmenopausal woman ( defined menses least 1 year postsurgical bilateral oophorectomy ) require undergo pregnancy test . 7 . FRP nonvasectomized male participant must agree use reliable contraception sexually active . ( For FRP 's , 'Adequate contraception ' defined combination least 2 effective method birth control , least one physical barrier ( e.g. , condom hormonal contraception implant combine oral contraceptive , certain intrauterine device ) . This applies time signing informed consent form one month last study drug administration . ) 8 . Oral corticosteroid ( ≤ 10 mg/day prednisone equivalent ) , nonsteroidal anti inflammatory drug ( NSAIDs ) , angiotensin receptor blocker , angiotensin convert enzyme ( ACE ) inhibitor calcium channel blocker permit participant stable dose ≥ 2 week prior include baseline visit 9 . Ability comply clinical visit schedule studyrelated procedure . 1 . Active DU relate calcinosis ( assessed clinical examination radiographic evaluation screen ) 2 . Medical surgical history Major surgery ( include joint surgery ) within 8 week prior screen Participants history malignancy last 5 year nonmelanoma skin cell cancer cure local resection carcinoma situ 3 . Hepaticrelated criterion Hepatic insufficiency classify ChildPugh C screening ( see Appendix 11.1 classification table ) screen visit 4 . Renalrelated criterion Estimated glomerular filtration rate ( eGFR ) &lt; 15 mL/min/1.73m2 ( MDRD formula ) dialysis screen visit Cardiovascularrelated criterion Sitting systolic blood pressure &lt; 95 mmHg screen visit Sitting heart rate &lt; 50 beat per minute ( BPM ) screen visit Left ventricular ejection fraction &lt; 40 % prior screening echocardiogram do part clinical care 5 . Pulmonaryrelated criterion Active state hemoptysis pulmonary hemorrhage , include event manage bronchial artery embolization Any history bronchial artery embolization massive hemoptysis within 3 month prior screen . Massive hemoptysis define acute bleeding &gt; 240 mL 24hour period recurrent bleed &gt; 100 mL/d several day PAH require pharmacologic therapy . Significant pulmonary disease FVC ≤ 50 % predict , DLCO ( uncorrected hemoglobin ) ≤ 40 % predict 6 . Laboratory examination Participants hemoglobin &lt; 9.0 g/dL , white blood cell ( WBC ) count &lt; 3000/mm3 ( &lt; 3 × 109/L ) , platelet count &lt; 100,000/mm3 ( &lt; 3 × 109/L ) screen visit 7 . Prior concomitant therapy Concomitant use nitrate NO donor ( amyl nitrate ) form , include topical ; phosphodiesterase ( PDE ) 5 ( PDE5 ) inhibitor ( sildenafil , tadalafil , vardenafil ) ; nonspecific PDE5 inhibitor ( theophylline , dipyridamole ) . If patient PDE5 inhibitor , wash 3 day require sildenafil 7 day tadalafil vardenafil prior baseline visit Concomitant Endothelin receptor antagonist Patients actively smoke time consent . ( Quit date two week prior screen acceptable ) 8 . Pregnant breastfeed woman 9 . Other Any condition therapy would make participant unsuitable study allow participation full plan study period Participation another clinical study investigational drug medical device within 30 day prior randomization ( phase IIII clinical study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Scleroderma</keyword>
	<keyword>Digital Ulcer</keyword>
</DOC>